This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharmaSGP Holding（PSG）株式概要PharmaSGP Holding SEは、ドイツで一般用医薬品やその他のヘルスケア製品を製造・販売している。 詳細PSG ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績2/6財務の健全性4/6配当金3/6報酬当社が推定した公正価値より25.5%で取引されている 過去5年間の収益は年間9.8%増加しました。 リスク分析多額の負債を抱えている すべてのリスクチェックを見るPSG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW491,774 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG491,774 investors already sharing narrativesYour Fair Value€Current Price€28.8051.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0254m2016201920222025202620282031Revenue €253.6mEarnings €40.9mAdvancedSet Fair ValueView all narrativesPharmaSGP Holding SE 競合他社Dermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.3bApontis PharmaSymbol: XTRA:APPHMarket cap: €91.6mMPH Health CareSymbol: DB:93M1Market cap: €104.5mMerck KGaASymbol: XTRA:MRKMarket cap: €60.7b価格と性能株価の高値、安値、推移の概要PharmaSGP Holding過去の株価現在の株価€28.8052週高値€29.6052週安値€19.00ベータ-0.0331ヶ月の変化1.41%3ヶ月変化6.67%1年変化46.19%3年間の変化10.34%5年間の変化-8.28%IPOからの変化-19.10%最新ニュースお知らせ • Jul 13PharmaSGP Holding SE Adjusts Earnings Guidance for the Full Year 2025PharmaSGP Holding SE adjusted earnings guidance for the full year 2025. For the year, the company decided, based on an evaluation of current data on business development completed, to adjust the forecast for consolidated revenues of the PharmaSGP Group for the full year 2025. In view of the business development to date, the Management Board now expects consolidated revenues for the 2025 fiscal year to be in the range of €132.0 million to €138.0 million. The company had previously forecasted consolidated revenues for the 2025 fiscal year in the range of €122.0 million to €128.0 million. The adjusted forecast for fiscal year 2025 continues to take into account, among other things, the ongoing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and potential consequences for Germany and Europe cannot be conclusively assessed at this time.お知らせ • Jul 11+ 1 more updatePharmaSGP Holding SE to Report First Half, 2025 Final Results on Sep 25, 2025PharmaSGP Holding SE announced that they will report first half, 2025 final results on Sep 25, 2025お知らせ • Jun 28PharmaSGP Holding SE Confirms Earnings Guidance for the Financial Year 2025PharmaSGP Holding SE confirmed earnings guidance for the financial year 2025. For the year, the company expects revenues in a range between €122.0 million and €128.0 million. This represents average growth of around 5% compared with the previous year.お知らせ • Jun 10Futrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) for €57 millionFutrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) from Mvh Beteiligungs- Und Beratungs-GmbH and others for €57.7 million on June 10, 2025. A cash consideration valued at €28 per share will be paid by Futrue GmbH. Upon completion, Futrue GmbH will own 100% stake in PharmaSGP Holding SE.お知らせ • May 15+ 2 more updatesPharmaSGP Holding SE, Annual General Meeting, Jun 25, 2025PharmaSGP Holding SE, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.お知らせ • Apr 16PharmaSGP Holding SE Provides Earnings Guidance for the Full Year 2025PharmaSGP Holding SE provided earnings guidance for the full year 2025. For the year, the company expects a further increase in revenues in a range between €122.0 million and €128.0 million.最新情報をもっと見るRecent updatesお知らせ • Jul 13PharmaSGP Holding SE Adjusts Earnings Guidance for the Full Year 2025PharmaSGP Holding SE adjusted earnings guidance for the full year 2025. For the year, the company decided, based on an evaluation of current data on business development completed, to adjust the forecast for consolidated revenues of the PharmaSGP Group for the full year 2025. In view of the business development to date, the Management Board now expects consolidated revenues for the 2025 fiscal year to be in the range of €132.0 million to €138.0 million. The company had previously forecasted consolidated revenues for the 2025 fiscal year in the range of €122.0 million to €128.0 million. The adjusted forecast for fiscal year 2025 continues to take into account, among other things, the ongoing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and potential consequences for Germany and Europe cannot be conclusively assessed at this time.お知らせ • Jul 11+ 1 more updatePharmaSGP Holding SE to Report First Half, 2025 Final Results on Sep 25, 2025PharmaSGP Holding SE announced that they will report first half, 2025 final results on Sep 25, 2025お知らせ • Jun 28PharmaSGP Holding SE Confirms Earnings Guidance for the Financial Year 2025PharmaSGP Holding SE confirmed earnings guidance for the financial year 2025. For the year, the company expects revenues in a range between €122.0 million and €128.0 million. This represents average growth of around 5% compared with the previous year.お知らせ • Jun 10Futrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) for €57 millionFutrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) from Mvh Beteiligungs- Und Beratungs-GmbH and others for €57.7 million on June 10, 2025. A cash consideration valued at €28 per share will be paid by Futrue GmbH. Upon completion, Futrue GmbH will own 100% stake in PharmaSGP Holding SE.お知らせ • May 15+ 2 more updatesPharmaSGP Holding SE, Annual General Meeting, Jun 25, 2025PharmaSGP Holding SE, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.お知らせ • Apr 16PharmaSGP Holding SE Provides Earnings Guidance for the Full Year 2025PharmaSGP Holding SE provided earnings guidance for the full year 2025. For the year, the company expects a further increase in revenues in a range between €122.0 million and €128.0 million.お知らせ • Apr 15PharmaSGP Holding SE to Report Fiscal Year 2024 Final Results on Apr 30, 2025PharmaSGP Holding SE announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 30, 2025お知らせ • Nov 14PharmaSGP Holding SE to Report Nine Months, 2024 Results on Nov 28, 2024PharmaSGP Holding SE announced that they will report nine months, 2024 results on Nov 28, 2024Reported Earnings • Sep 26Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: EPS: €0.34 (up from €0.33 in 2Q 2023). Revenue: €28.2m (up 9.8% from 2Q 2023). Net income: €4.12m (up 2.5% from 2Q 2023). Profit margin: 15% (down from 16% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.9%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Sep 12PharmaSGP Holding SE to Report First Half, 2024 Results on Sep 26, 2024PharmaSGP Holding SE announced that they will report first half, 2024 results on Sep 26, 2024Price Target Changed • Jun 15Price target increased by 9.2% to €38.75Up from €35.50, the current price target is an average from 2 analysts. New target price is 76% above last closing price of €22.00. Stock is down 22% over the past year. The company is forecast to post earnings per share of €1.57 for next year compared to €1.37 last year.Reported Earnings • May 29First quarter 2024 earnings released: EPS: €0.38 (vs €0.24 in 1Q 2023)First quarter 2024 results: EPS: €0.38 (up from €0.24 in 1Q 2023). Revenue: €30.2m (up 26% from 1Q 2023). Net income: €4.56m (up 60% from 1Q 2023). Profit margin: 15% (up from 12% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • May 18PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024, at 10:00 W. Europe Standard Time.Reported Earnings • Apr 30Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: EPS: €1.37 (up from €1.00 in FY 2022). Revenue: €101.3m (up 18% from FY 2022). Net income: €16.4m (up 37% from FY 2022). Profit margin: 16% (up from 14% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Declared Dividend • Apr 23Dividend of €1.36 announcedShareholders will receive a dividend of €1.36. Ex-date: 27th June 2024 Payment date: 1st July 2024 Dividend yield will be 6.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (39% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 4.3% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 21PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023The Management Board and Supervisory Board of PharmaSGP Holding SE will propose to this year’s Annual General Meeting of the company a one-time increased dividend of EUR 1.36 per dividend-bearing share for the past financial year 2023 (previous year: EUR 0.49). Excluding treasury shares, this corresponds to a total distribution of EUR 16,320,000.00 or around 99.5% of the consolidated net income for 2023 (previous year: EUR 5,875,241.12 or 49.2% of the consolidated net income for 2022). This was decided by the Management Board and Supervisory Board.お知らせ • Apr 20PharmaSGP Holding SE Announces Changes to Dividend PolicyPharmaSGP Holding SE intended to return to its previous dividend policy, according to which the distribution is generally between 30% and 50% of the consolidated net income.お知らせ • Apr 16PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024PharmaSGP Holding SE announced that they will report fiscal year 2023 results on Apr 29, 2024Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €23.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 23% over the past three years.Reported Earnings • Dec 01Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: €0.40 (up from €0.33 in 3Q 2022). Revenue: €26.0m (up 18% from 3Q 2022). Net income: €4.79m (up 21% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Revenue exceeded analyst estimates by 6.0%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 02Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)Second quarter 2023 results: EPS: €0.33 (up from €0.25 in 2Q 2022). Revenue: €25.8m (up 20% from 2Q 2022). Net income: €4.02m (up 35% from 2Q 2022). Profit margin: 16% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 8% per year, which means it is performing significantly worse than earnings.Upcoming Dividend • Jun 22Upcoming dividend of €0.49 per share at 1.7% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.6%).New Risk • Jun 15New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 130% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (130% net debt to equity). Short dividend paying track record (1 year of continuous dividend payments).Price Target Changed • May 17Price target increased by 7.2% to €37.00Up from €34.50, the current price target is an average from 2 analysts. New target price is 32% above last closing price of €28.10. Stock is up 18% over the past year. The company is forecast to post earnings per share of €1.17 for next year compared to €1.00 last year.Price Target Changed • Apr 01Price target increased by 9.2% to €35.50Up from €32.50, the current price target is an average from 2 analysts. New target price is 29% above last closing price of €27.50. Stock is up 27% over the past year. The company is forecast to post earnings per share of €0.93 for next year compared to €0.89 last year.お知らせ • Jan 10PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.PharmaSGP Holding SE (XTRA:PSG) commences a share repurchases on January 4, 2023, under the program mandated by the shareholders in the Annual General Meeting held on May 28, 2020. As per the mandate, the company is authorized to repurchase its own shares. On January 3, 2023, the company announced a share repurchase program. Under the program, the company will repurchase up to 60,000 shares, for €1.5 million. The company intends to use the repurchased shares in accordance with the authorization of the General Meeting of May 28, 2020 for all legally permissible purposes. The program will start on January 4, 2023 and terminate at the end of July 3, 2023 at the latest.Reported Earnings • Jun 02First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2022 results: EPS: €0.14 (up from €0.10 in 1Q 2021). Revenue: €20.6m (up 67% from 1Q 2021). Net income: €1.68m (up 43% from 1Q 2021). Profit margin: 8.2% (down from 9.5% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 12%, compared to a 6.9% growth forecast for the industry in Germany.Reported Earnings • May 01Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €0.89 (up from €0.89 in FY 2020). Revenue: €65.5m (up 3.6% from FY 2020). Net income: €10.7m (flat on FY 2020). Profit margin: 16% (in line with FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 18%, compared to a 8.1% growth forecast for the pharmaceuticals industry in Germany.Reported Earnings • Dec 02Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2021 results: EPS: €0.34 (up from €0.29 in 3Q 2020). Revenue: €19.9m (up 52% from 3Q 2020). Net income: €4.10m (up 20% from 3Q 2020). Profit margin: 21% (down from 26% in 3Q 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 6.3%. Earnings per share (EPS) missed analyst estimates by 6.3%. Over the next year, revenue is forecast to grow 16%, compared to a 6.9% growth forecast for the industry in Germany.Reported Earnings • Oct 01Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)The company reported a poor second quarter result with weaker earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €14.2m (down 24% from 2Q 2020). Net income: €3.02m (down 22% from 2Q 2020). Profit margin: 21% (in line with 2Q 2020).Reported Earnings • May 28First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: €12.4m (down 26% from 1Q 2020). Net income: €1.18m (down 64% from 1Q 2020). Profit margin: 9.5% (down from 19% in 1Q 2020). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • May 17Investor sentiment improved over the past weekAfter last week's 15% share price gain to €18.85, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe.Reported Earnings • May 03Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €64.9m (up 3.7% from FY 2019). Net income: €10.6m (down 36% from FY 2019). Profit margin: 16% (down from 27% in FY 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Feb 18New 90-day low: €19.80The company is down 27% from its price of €26.95 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 16% share price gain to €23.20, the stock is trading at a trailing P/E ratio of 16.7x, up from the previous P/E ratio of 14.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe.Valuation Update With 7 Day Price Move • Dec 07Market pulls back on stock over the past weekAfter last week's 18% share price decline to €20.50, the stock is trading at a trailing P/E ratio of 15.4x, down from the previous P/E ratio of 18.7x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe.Is New 90 Day High Low • Nov 24New 90-day low: €26.90The company is down 8.0% from its price of €29.35 on 25 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: €29.10The company is down 4.0% from its price of €30.20 on 31 July 2020. The German market is also down 4.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Pharmaceuticals industry, which is down 4.0% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total profits of €16.9m, up 7.7% from the prior year. Total revenue was €66.5m over the last 12 months, up 8.0% from the prior year.株主還元PSGDE PharmaceuticalsDE 市場7D0%-4.9%-2.5%1Y46.2%43.9%-0.6%株主還元を見る業界別リターン: PSG過去 1 年間で43.9 % の収益を上げたGerman Pharmaceuticals業界を上回りました。リターン対市場: PSG過去 1 年間で-0.6 % の収益を上げたGerman市場を上回りました。価格変動Is PSG's price volatile compared to industry and market?PSG volatilityPSG Average Weekly Movement2.5%Pharmaceuticals Industry Average Movement5.8%Market Average Movement5.4%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.8%安定した株価: PSG 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: PSGの 週次ボラティリティ ( 2% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201991Peter Gerckenspharmasgp.comPharmaSGPホールディングSEは、ドイツで一般用医薬品やその他のヘルスケア製品を製造・販売している。同社の医薬品には、睡眠障害治療薬Baldriparan、様々な疼痛症状治療薬Spalt、Formigran、Kamolマッサージクリーム、骨、腱、筋肉のリウマチ性疼痛治療薬RubaXX医薬品ドロップ、首や背中の神経痛治療薬Restaxil医薬品ドロップなどがある；脱毛治療薬「レビテンシン」、神経痛・頭痛・片頭痛治療薬「ドリゾール」、美容ドリンク「フルミナン」、不快な症状に効く点滴薬「リンデン」、脳血管の詰まり治療薬「スクレロカルマン」などがある。また、良性前立腺肥大の膀胱炎や排尿時の不快感に効く薬「プロスタカルマン」、結合組織の弱い女性のための「レボテン」、健康な循環器系のための微量栄養素飲料「ミンダリン」、不安、落ち着きのなさ、気分の落ち込みを治療する処方箋不要の錠剤「メリストン」などもある；皮膚の赤み用クリーム「デルバ」、新たな色素斑の形成を防ぐ「レンティゾール」、頭痛用錠剤「ネオドール」、性欲減退用医薬品「デセオ」、性機能障害治療薬「ネラジン」、めまい治療薬「タウメア」。同社は薬局や卸売業者を通じて製品を販売している。また、オーストリア、イタリア、ベルギー、スペイン、フランスを含む欧州諸国に製品を輸出している。同社は2012年に設立され、ドイツのグレーフェルフィングに本社を置いている。もっと見るPharmaSGP Holding SE 基礎のまとめPharmaSGP Holding の収益と売上を時価総額と比較するとどうか。PSG 基礎統計学時価総額€345.38m収益（TTM）€19.71m売上高(TTM)€122.10m17.5xPER（株価収益率2.8xP/SレシオPSG は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PSG 損益計算書（TTM）収益€122.10m売上原価€11.54m売上総利益€110.56mその他の費用€90.85m収益€19.71m直近の収益報告Mar 31, 2025次回決算日Sep 11, 2025一株当たり利益（EPS）1.71グロス・マージン90.55%純利益率16.14%有利子負債／自己資本比率178.5%PSG の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.7%現在の配当利回り30%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/23 15:17終値2025/08/11 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PharmaSGP Holding SE 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Gerhard OrgonasBerenbergCharles WestonRBC Capital MarketsJack Reynolds-ClarkRBC Capital Markets
お知らせ • Jul 13PharmaSGP Holding SE Adjusts Earnings Guidance for the Full Year 2025PharmaSGP Holding SE adjusted earnings guidance for the full year 2025. For the year, the company decided, based on an evaluation of current data on business development completed, to adjust the forecast for consolidated revenues of the PharmaSGP Group for the full year 2025. In view of the business development to date, the Management Board now expects consolidated revenues for the 2025 fiscal year to be in the range of €132.0 million to €138.0 million. The company had previously forecasted consolidated revenues for the 2025 fiscal year in the range of €122.0 million to €128.0 million. The adjusted forecast for fiscal year 2025 continues to take into account, among other things, the ongoing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and potential consequences for Germany and Europe cannot be conclusively assessed at this time.
お知らせ • Jul 11+ 1 more updatePharmaSGP Holding SE to Report First Half, 2025 Final Results on Sep 25, 2025PharmaSGP Holding SE announced that they will report first half, 2025 final results on Sep 25, 2025
お知らせ • Jun 28PharmaSGP Holding SE Confirms Earnings Guidance for the Financial Year 2025PharmaSGP Holding SE confirmed earnings guidance for the financial year 2025. For the year, the company expects revenues in a range between €122.0 million and €128.0 million. This represents average growth of around 5% compared with the previous year.
お知らせ • Jun 10Futrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) for €57 millionFutrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) from Mvh Beteiligungs- Und Beratungs-GmbH and others for €57.7 million on June 10, 2025. A cash consideration valued at €28 per share will be paid by Futrue GmbH. Upon completion, Futrue GmbH will own 100% stake in PharmaSGP Holding SE.
お知らせ • May 15+ 2 more updatesPharmaSGP Holding SE, Annual General Meeting, Jun 25, 2025PharmaSGP Holding SE, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Apr 16PharmaSGP Holding SE Provides Earnings Guidance for the Full Year 2025PharmaSGP Holding SE provided earnings guidance for the full year 2025. For the year, the company expects a further increase in revenues in a range between €122.0 million and €128.0 million.
お知らせ • Jul 13PharmaSGP Holding SE Adjusts Earnings Guidance for the Full Year 2025PharmaSGP Holding SE adjusted earnings guidance for the full year 2025. For the year, the company decided, based on an evaluation of current data on business development completed, to adjust the forecast for consolidated revenues of the PharmaSGP Group for the full year 2025. In view of the business development to date, the Management Board now expects consolidated revenues for the 2025 fiscal year to be in the range of €132.0 million to €138.0 million. The company had previously forecasted consolidated revenues for the 2025 fiscal year in the range of €122.0 million to €128.0 million. The adjusted forecast for fiscal year 2025 continues to take into account, among other things, the ongoing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and potential consequences for Germany and Europe cannot be conclusively assessed at this time.
お知らせ • Jul 11+ 1 more updatePharmaSGP Holding SE to Report First Half, 2025 Final Results on Sep 25, 2025PharmaSGP Holding SE announced that they will report first half, 2025 final results on Sep 25, 2025
お知らせ • Jun 28PharmaSGP Holding SE Confirms Earnings Guidance for the Financial Year 2025PharmaSGP Holding SE confirmed earnings guidance for the financial year 2025. For the year, the company expects revenues in a range between €122.0 million and €128.0 million. This represents average growth of around 5% compared with the previous year.
お知らせ • Jun 10Futrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) for €57 millionFutrue GmbH proposed to acquire remaining 17.91% stake in PharmaSGP Holding SE (XTRA:PSG) from Mvh Beteiligungs- Und Beratungs-GmbH and others for €57.7 million on June 10, 2025. A cash consideration valued at €28 per share will be paid by Futrue GmbH. Upon completion, Futrue GmbH will own 100% stake in PharmaSGP Holding SE.
お知らせ • May 15+ 2 more updatesPharmaSGP Holding SE, Annual General Meeting, Jun 25, 2025PharmaSGP Holding SE, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Apr 16PharmaSGP Holding SE Provides Earnings Guidance for the Full Year 2025PharmaSGP Holding SE provided earnings guidance for the full year 2025. For the year, the company expects a further increase in revenues in a range between €122.0 million and €128.0 million.
お知らせ • Apr 15PharmaSGP Holding SE to Report Fiscal Year 2024 Final Results on Apr 30, 2025PharmaSGP Holding SE announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 30, 2025
お知らせ • Nov 14PharmaSGP Holding SE to Report Nine Months, 2024 Results on Nov 28, 2024PharmaSGP Holding SE announced that they will report nine months, 2024 results on Nov 28, 2024
Reported Earnings • Sep 26Second quarter 2024 earnings: EPS misses analyst expectationsSecond quarter 2024 results: EPS: €0.34 (up from €0.33 in 2Q 2023). Revenue: €28.2m (up 9.8% from 2Q 2023). Net income: €4.12m (up 2.5% from 2Q 2023). Profit margin: 15% (down from 16% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.9%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Sep 12PharmaSGP Holding SE to Report First Half, 2024 Results on Sep 26, 2024PharmaSGP Holding SE announced that they will report first half, 2024 results on Sep 26, 2024
Price Target Changed • Jun 15Price target increased by 9.2% to €38.75Up from €35.50, the current price target is an average from 2 analysts. New target price is 76% above last closing price of €22.00. Stock is down 22% over the past year. The company is forecast to post earnings per share of €1.57 for next year compared to €1.37 last year.
Reported Earnings • May 29First quarter 2024 earnings released: EPS: €0.38 (vs €0.24 in 1Q 2023)First quarter 2024 results: EPS: €0.38 (up from €0.24 in 1Q 2023). Revenue: €30.2m (up 26% from 1Q 2023). Net income: €4.56m (up 60% from 1Q 2023). Profit margin: 15% (up from 12% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • May 18PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024, at 10:00 W. Europe Standard Time.
Reported Earnings • Apr 30Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: EPS: €1.37 (up from €1.00 in FY 2022). Revenue: €101.3m (up 18% from FY 2022). Net income: €16.4m (up 37% from FY 2022). Profit margin: 16% (up from 14% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Apr 23Dividend of €1.36 announcedShareholders will receive a dividend of €1.36. Ex-date: 27th June 2024 Payment date: 1st July 2024 Dividend yield will be 6.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (39% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 4.3% per year over the past 2 years and payments have been stable during that time. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 21PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023The Management Board and Supervisory Board of PharmaSGP Holding SE will propose to this year’s Annual General Meeting of the company a one-time increased dividend of EUR 1.36 per dividend-bearing share for the past financial year 2023 (previous year: EUR 0.49). Excluding treasury shares, this corresponds to a total distribution of EUR 16,320,000.00 or around 99.5% of the consolidated net income for 2023 (previous year: EUR 5,875,241.12 or 49.2% of the consolidated net income for 2022). This was decided by the Management Board and Supervisory Board.
お知らせ • Apr 20PharmaSGP Holding SE Announces Changes to Dividend PolicyPharmaSGP Holding SE intended to return to its previous dividend policy, according to which the distribution is generally between 30% and 50% of the consolidated net income.
お知らせ • Apr 16PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024PharmaSGP Holding SE announced that they will report fiscal year 2023 results on Apr 29, 2024
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €23.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 23% over the past three years.
Reported Earnings • Dec 01Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: €0.40 (up from €0.33 in 3Q 2022). Revenue: €26.0m (up 18% from 3Q 2022). Net income: €4.79m (up 21% from 3Q 2022). Profit margin: 18% (in line with 3Q 2022). Revenue exceeded analyst estimates by 6.0%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 02Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)Second quarter 2023 results: EPS: €0.33 (up from €0.25 in 2Q 2022). Revenue: €25.8m (up 20% from 2Q 2022). Net income: €4.02m (up 35% from 2Q 2022). Profit margin: 16% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 8% per year, which means it is performing significantly worse than earnings.
Upcoming Dividend • Jun 22Upcoming dividend of €0.49 per share at 1.7% yieldEligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.6%).
New Risk • Jun 15New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 130% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (130% net debt to equity). Short dividend paying track record (1 year of continuous dividend payments).
Price Target Changed • May 17Price target increased by 7.2% to €37.00Up from €34.50, the current price target is an average from 2 analysts. New target price is 32% above last closing price of €28.10. Stock is up 18% over the past year. The company is forecast to post earnings per share of €1.17 for next year compared to €1.00 last year.
Price Target Changed • Apr 01Price target increased by 9.2% to €35.50Up from €32.50, the current price target is an average from 2 analysts. New target price is 29% above last closing price of €27.50. Stock is up 27% over the past year. The company is forecast to post earnings per share of €0.93 for next year compared to €0.89 last year.
お知らせ • Jan 10PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.PharmaSGP Holding SE (XTRA:PSG) commences a share repurchases on January 4, 2023, under the program mandated by the shareholders in the Annual General Meeting held on May 28, 2020. As per the mandate, the company is authorized to repurchase its own shares. On January 3, 2023, the company announced a share repurchase program. Under the program, the company will repurchase up to 60,000 shares, for €1.5 million. The company intends to use the repurchased shares in accordance with the authorization of the General Meeting of May 28, 2020 for all legally permissible purposes. The program will start on January 4, 2023 and terminate at the end of July 3, 2023 at the latest.
Reported Earnings • Jun 02First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2022 results: EPS: €0.14 (up from €0.10 in 1Q 2021). Revenue: €20.6m (up 67% from 1Q 2021). Net income: €1.68m (up 43% from 1Q 2021). Profit margin: 8.2% (down from 9.5% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 12%, compared to a 6.9% growth forecast for the industry in Germany.
Reported Earnings • May 01Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €0.89 (up from €0.89 in FY 2020). Revenue: €65.5m (up 3.6% from FY 2020). Net income: €10.7m (flat on FY 2020). Profit margin: 16% (in line with FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 18%, compared to a 8.1% growth forecast for the pharmaceuticals industry in Germany.
Reported Earnings • Dec 02Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2021 results: EPS: €0.34 (up from €0.29 in 3Q 2020). Revenue: €19.9m (up 52% from 3Q 2020). Net income: €4.10m (up 20% from 3Q 2020). Profit margin: 21% (down from 26% in 3Q 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 6.3%. Earnings per share (EPS) missed analyst estimates by 6.3%. Over the next year, revenue is forecast to grow 16%, compared to a 6.9% growth forecast for the industry in Germany.
Reported Earnings • Oct 01Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)The company reported a poor second quarter result with weaker earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €14.2m (down 24% from 2Q 2020). Net income: €3.02m (down 22% from 2Q 2020). Profit margin: 21% (in line with 2Q 2020).
Reported Earnings • May 28First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: €12.4m (down 26% from 1Q 2020). Net income: €1.18m (down 64% from 1Q 2020). Profit margin: 9.5% (down from 19% in 1Q 2020). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • May 17Investor sentiment improved over the past weekAfter last week's 15% share price gain to €18.85, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe.
Reported Earnings • May 03Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €64.9m (up 3.7% from FY 2019). Net income: €10.6m (down 36% from FY 2019). Profit margin: 16% (down from 27% in FY 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Feb 18New 90-day low: €19.80The company is down 27% from its price of €26.95 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 16% share price gain to €23.20, the stock is trading at a trailing P/E ratio of 16.7x, up from the previous P/E ratio of 14.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe.
Valuation Update With 7 Day Price Move • Dec 07Market pulls back on stock over the past weekAfter last week's 18% share price decline to €20.50, the stock is trading at a trailing P/E ratio of 15.4x, down from the previous P/E ratio of 18.7x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe.
Is New 90 Day High Low • Nov 24New 90-day low: €26.90The company is down 8.0% from its price of €29.35 on 25 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: €29.10The company is down 4.0% from its price of €30.20 on 31 July 2020. The German market is also down 4.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Pharmaceuticals industry, which is down 4.0% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total profits of €16.9m, up 7.7% from the prior year. Total revenue was €66.5m over the last 12 months, up 8.0% from the prior year.
